By JUDY NEWMAN 608-252-6156
Third Wave Technologies has hit a major milestone, and at least one expert is
predicting it will send the Madison biotechnology company's stock soaring
today. Third Wave said Tuesday it has completed human clinical trials on its test
for the human papillomavirus (HPV), often a precursor of cervical cancer. More
than 3,400 women were screened at 47 sites and Third Wave's test, which screens
for 14 high-risk types of HPV, demonstrated a 99 percent likelihood that women
with a negative test result do not have cervical disease, the company said. The results will be submitted to the U.S. Food and Drug Administration in
April.
